Alex Wiltschko, PhD

Speaker: Alex Wiltschko, PhD, CEO of Osmo, and an entrepreneur in residence at GV


Talk Title: The Cognitive Revolution: Entering an Era of Automating Both Muscles and Minds.

Alex Wiltschko is the CEO of Osmo, and an entrepreneur in residence at GV. He joined the life sciences team in 2022, where he's focused on advancing the field of digital olfaction. He is also the co-host of the Theory and Practice podcast alongside GV venture partner Anthony Philippakis. The podcast features conversations at the cutting edge of biology and computer science.

Previously, Alex was a staff research scientist at Google Research, where he worked at the intersection of machine learning and biology since 2017.

Alex is a repeat entrepreneur who has spent much of his career exploring new frontiers in artificial intelligence. Before Google, Alex co-founded Syllable Life Sciences (acquired by Neumora), which used AI and computer vision to decipher body language to accelerate preclinical development and build better treatments for disease. Alex was also the co-founder of Whetlab (acquired by Twitter) and spent the earlier years of his career as a software developer.

Alex holds a Ph.D. in Neuroscience from Harvard University, where he studied olfactory neuroscience and developed next-generation high-throughput behavioral phenotyping technologies now used in dozens of top-tier labs and pharma companies. He received his B.S. degree in Neuroscience from the University of Michigan


Keloth VK, Banda JM, Gurley M, Heider PM, Kennedy G, Liu H, Liu F, Miller T, Natarajan K, V Patterson O, Peng Y, Raja K, Reeves RM, Rouhizadeh M, Shi J, Wang X, Wang Y, Wei WQ, Williams AE, Zhang R, Belenkaya R, Reich C, Blacketer C, Ryan P, Hripcsak G, Elhadad N, Xu H. Representing and Utilizing Clinical Textual Data for Real World Studies: An OHDSI Approach. Journal of biomedical informatics 2023.

Toce MS, Michelson KA, Hudgins JD, Olson KL, Monuteaux MC, Bourgeois FT. Association of prescription drug monitoring programs with benzodiazepine prescription dispensation and overdose in adolescents and young adults. Clinical toxicology (Philadelphia, Pa.) 2023.

Brown T, de Salazar Munoz PM, Bhatia A, Bunda B, Williams EK, Bor D, Miller JS, Mohareb A, Thierauf J, Yang W, Villalba J, Naranbai V, Garcia Beltran W, Miller TE, Kress D, Stelljes K, Johnson K, Larremore D, Lennerz J, Iafrate AJ, Balsari S, Buckee C, Grad Y. Geographically skewed recruitment and COVID-19 seroprevalence estimates: a cross-sectional serosurveillance study and mathematical modelling analysis. BMJ open 2023.

El-Hayek C, Barzegar S, Faux N, Doyle K, Pillai P, Mutch SJ, Vaisey A, Ward R, Sanci L, Dunn AG, Hellard ME, Hocking JS, Verspoor K, Boyle DI. An evaluation of existing text de-identification tools for use with patient progress notes from Australian general practice. International journal of medical informatics 2023.

Patik I, Redhu NS, Eran A, Bao B, Nandy A, Tang Y, El Sayed S, Shen Z, Glickman J, Fox JG, Snapper SB, Horwitz BH. The IL-10 receptor inhibits cell extrinsic signals necessary for STAT1-dependent macrophage accumulation during colitis. Mucosal immunology 2023.